Characteristics of patients with DM using icosapent ethyl in the real world
Om P. Ganda, MD
The effect of icosapent ethyl on CV events in metabolic syndrome
Michael Miller, MD
Perspectives on the results of recent clinical outcomes trials with EPA prevention
P. Gabriel Steg, MD
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Pam R. Taub, MD, FACC, FASPC
Loading...
We’re glad to see you’re enjoying PACE-CME…but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.